TY - JOUR
T1 - High-fat diet-induced neuropathy of pre-diabetes and obesity
T2 - Effects of "healthy" diet and aldose reductase inhibition
AU - Obrosova, Irina G.
AU - Ilnytska, Olga
AU - Lyzogubov, Valeriy V.
AU - Pavlov, Ivan A.
AU - Mashtalir, Nazar
AU - Nadler, Jerry L.
AU - Drel, Viktor R.
PY - 2007/10
Y1 - 2007/10
N2 - OBJECTIVE - Subjects with dietary obesity and pre-diabetes have an increased risk for developing both nerve conduction slowing and small sensory fiber neuropathy. Animal models of this type of neuropathy have not been described. This study evaluated neuropathic changes and their amenability to dietary and pharmacological interventions in mice fed a high-fat diet (HFD), a model of pre-diabetes and alimentary obesity. RESEARCH DESIGN AND METHODS - Female C57BL6/J mice were fed normal diets or HFDs for 16 weeks. RESULTS - HFD-fed mice developed obesity, increased plasma FFA and insulin concentrations, and impaired glucose tolerance. They also had motor and sensory nerve conduction deficits, tactile allodynia, and thermal hypoalgesia in the absence of intraepidermal nerve fiber loss or axonal atrophy. Despite the absence of overt hyperglycemia, the mice displayed augmented sorbitol pathway activity in the peripheral nerve, as well as 4-hydroxynonenal adduct nitrotyrosine and poly(ADP-ribose) accumulation and 12/15-lipoxygenase overexpression in peripheral nerve and dorsal root ganglion neurons. A 6-week feeding with normal chow after 16 weeks on HFD alleviated tactile allodynia and essentially corrected thermal hypoalgesia and sensory nerve conduction deficit without affecting motor nerve conduction slowing. Normal chow containing the aldose reductase inhibitor fidarestat (16 mg · kg-1 · day -1) corrected all functional changes of HFD-induced neuropathy. CONCLUSIONS - Similar to human subjects with pre-diabetes and obesity, HFD-fed mice develop peripheral nerve functional, but not structural, abnormalities and, therefore, are a suitable model for evaluating dietary and pharmacological approaches to halt progression and reverse diabetic neuropathy at the earliest stage of the disease.
AB - OBJECTIVE - Subjects with dietary obesity and pre-diabetes have an increased risk for developing both nerve conduction slowing and small sensory fiber neuropathy. Animal models of this type of neuropathy have not been described. This study evaluated neuropathic changes and their amenability to dietary and pharmacological interventions in mice fed a high-fat diet (HFD), a model of pre-diabetes and alimentary obesity. RESEARCH DESIGN AND METHODS - Female C57BL6/J mice were fed normal diets or HFDs for 16 weeks. RESULTS - HFD-fed mice developed obesity, increased plasma FFA and insulin concentrations, and impaired glucose tolerance. They also had motor and sensory nerve conduction deficits, tactile allodynia, and thermal hypoalgesia in the absence of intraepidermal nerve fiber loss or axonal atrophy. Despite the absence of overt hyperglycemia, the mice displayed augmented sorbitol pathway activity in the peripheral nerve, as well as 4-hydroxynonenal adduct nitrotyrosine and poly(ADP-ribose) accumulation and 12/15-lipoxygenase overexpression in peripheral nerve and dorsal root ganglion neurons. A 6-week feeding with normal chow after 16 weeks on HFD alleviated tactile allodynia and essentially corrected thermal hypoalgesia and sensory nerve conduction deficit without affecting motor nerve conduction slowing. Normal chow containing the aldose reductase inhibitor fidarestat (16 mg · kg-1 · day -1) corrected all functional changes of HFD-induced neuropathy. CONCLUSIONS - Similar to human subjects with pre-diabetes and obesity, HFD-fed mice develop peripheral nerve functional, but not structural, abnormalities and, therefore, are a suitable model for evaluating dietary and pharmacological approaches to halt progression and reverse diabetic neuropathy at the earliest stage of the disease.
UR - http://www.scopus.com/inward/record.url?scp=34547399482&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34547399482&partnerID=8YFLogxK
U2 - 10.2337/db06-1176
DO - 10.2337/db06-1176
M3 - Article
C2 - 17626889
AN - SCOPUS:34547399482
SN - 0012-1797
VL - 56
SP - 2598
EP - 2608
JO - Diabetes
JF - Diabetes
IS - 10
ER -